Beta Bionics, Inc.·4

Sep 9, 4:12 PM ET

Feider Stephen 4

4 · Beta Bionics, Inc. · Filed Sep 9, 2025

Insider Transaction Report

Form 4
Period: 2025-09-08
Feider Stephen
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    2025-09-089,90089,695 total
    Exercise: $5.10Exp: 2033-09-13Common Stock (9,900 underlying)
  • Sale

    Common Stock

    2025-09-08$21.13/sh9,900$209,15144,041 total
  • Exercise/Conversion

    Common Stock

    2025-09-08$5.10/sh+9,900$50,49053,941 total
Footnotes (3)
  • [F1]Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025.
  • [F2]The weighted average sale price for the transaction reported was $21.126480 and the range of prices were between $21.00 and $21.2933. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • [F3]The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.

Documents

1 file
  • 4
    form4-09092025_080923.xmlPrimary